SARIZOTAN HYDROCHLORIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C22H21FN2O.ClH
Molecular Weight	384.874
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.FC1=CC=C(C=C1)C2=CN=CC(CNC[C@H]3CCC4=C(O3)C=CC=C4)=C2

InChI

InChIKey=QDLVYMYXOLGZOD-ZMBIFBSDSA-N

InChI=1S/C22H21FN2O.ClH/c23-20-8-5-17(6-9-20)19-11-16(12-24-14-19)13-25-15-21-10-7-18-3-1-2-4-22(18)26-21;/h1-6,8-9,11-12,14,21,25H,7,10,13,15H2;1H/t21-;/m1./s1

HIDE SMILES / InChI

Molecular Formula	C22H21FN2O
Molecular Weight	348.4133
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.businesswire.com/news/home/20150714005335/en/Newron-Receives-FDA-Orphan-Drug-Designation-Sarizotan | http://www.pharmatimes.com/news/merck_drops_late-stage_parkinsons_drug_996337 | https://clinicaltrials.gov/ct2/show/NCT02790034

Sarizotan (also known as EMD-128,130), a chromane derivative that was developed as a selective 5-HT1A receptor agonist and D2 receptor antagonist. Experiments on animal models have shown that the drug effectively suppressed levodopa-induced dyskinesia in primate and rodent models of Parkinson's disease, and tardive dyskinesia in a rodent model. Sarizotan participated in phase II/III clinical trials in the treatment of dyskinesia associated with the dopaminergic treatment of Parkinson's disease. However, further development for this disease was discontinued by Merk, because phase III did not confirm earlier Phase II findings. On July 14, 2015, Newron Pharmaceuticals, research, and development company focused on the novel central nervous system (CNS) and pain therapies, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to sarizotan for treatment of Rett syndrome. Besides, the drug now is an ongoing clinical trial phase II/III to investigate its the tolerability and efficacy in reducing respiratory abnormalities in Rett Syndrome.

Originator

Approval Year

PubMed

Title	Date	PubMed
Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models.	2001 Nov 27	11723272
Evaluation of EMD 128 130 occupancy of the 5-HT1A and the D2 receptor: a human PET study with [11C]WAY-100635 and [11C]raclopride.	2002 Sep	12236624
Contribution of the serotonin 5-HT1A receptor agonism of 8-OH-DPAT and EMD 128130 to the regulation of haloperidol-induced muscle rigidity in rats.	2003 Dec	14614949
Gateways to clinical trials.	2003 May	12808477
Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile.	2004 Feb	14767715
Drugs in development for Parkinson's disease.	2004 Jul	15298067
Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study).	2004 Mar-Apr	15252265
In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability.	2006 Dec	16959959
Investigation of the impact of sarizotan on the pharmacokinetics of levodopa.	2007 Oct	17654694
Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats.	2009 Jun	19159919

Patents

Sample Use Guides

In Vivo Use Guide

Subjects will receive sarizotan 1 milligram orally twice daily for 24 weeks.

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Fri Dec 15 17:20:49 GMT 2023` Edited by `admin` on `Fri Dec 15 17:20:49 GMT 2023`
Record UNII	5P71E6YO9H
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SARIZOTAN HYDROCHLORIDE

Official Name

English

EMD-128130

Code

English

3-PYRIDINEMETHANAMINE, N-(((2R)-3,4-DIHYDRO-2H-1-BENZOPYRAN-2-YL)METHYL)-5-(4-FLUOROPHENYL)-, MONOHYDROCHLORIDE

Common Name

English

(-)-N-(((2R)-3,4-DIHYDRO-2H-1-BENZOPYRAN-2-YL)METHYL)-5-(4-FLUOROPHENYL)PYRIDINE-3-YL)METHANAMINE MONOHYDROCHLORIDE

Common Name

English

SARIZOTAN HYDROCHLORIDE [USAN]

Common Name

English

SARIZOTAN HCL

Common Name

English

EMD 128130

Code

English

3-PYRIDINEMETHANAMINE, N-(((2R)-3,4-DIHYDRO-2H-1-BENZOPYRAN-2-YL)METHYL)-5-(4-FLUOROPHENYL)-, HYDROCHLORIDE (1:1)

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1509